At what enterprise value was BIOGARAN acquired in 2025?

During the acquisition of BIOGARAN by BC PARTNERS in 2025, the transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR.

What was the EV/EBITDA of BIOGARAN when it was acquired by BC PARTNERS?

The estimated EV/EBITDA multiple for BIOGARAN is in the range of 5x - 12x.

When was BIOGARAN acquired by BC PARTNERS?

BIOGARAN was acquired by BC PARTNERS in 2025.

What was the revenue of BIOGARAN at the time of the deal?

The revenue of BIOGARAN at the time of the deal is estimated to be in the range of 500M - 1b EUR.

What was the EBITDA of BIOGARAN during the acquisition?

BIOGARAN's EBITDA is estimated to be in the range of 100M - 200M EUR.

How is the data for the BIOGARAN acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the BIOGARAN deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/bc-partners-sapprete-a-racheter-biogaran-a-servier-2179228

← DATABASE

Home Database Healthcare & PharmaBIOGARAN

07/2025

BIOGARAN acquired by BC PARTNERS

FRANCE Life Sciences / Pharma & Biotech EV 500M - 1.5b EUR

Context

BC Partners, a leading European investment firm, and Bpifrance have finalized the landmark acquisition of Biogaran from Servier. As a cornerstone of the French pharmaceutical industry and the domestic leader in generic medicines, Biogaran enters a new phase of independence. The transaction was completed on January 30, 2026, following regulatory approvals and strict oversight regarding foreign investment in France.

BIOGARAN, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Biogaran is the undisputed market leader in the French generic pharmaceutical and biosimilars sector, commanding an estimated 30% market share. Founded in 1996 and based in France, the company operates as a key commercial subsidiary of Servier Laboratories. Its robust business model centers on the commercialization of an extensive portfolio of over 900 pharmaceutical products covering nearly all therapeutic areas, distributed nationwide through a network of more than 10,000 retail pharmacies. The company differentiates itself through a resilient, localized supply chain, with over 50% of its manufacturing based in France and 90% within Europe.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2025	PAI PARTNERS	Innovad Group	BELGIUM	Animal Health
08/2025	LGT CAPITAL PARTNERS	NEMERA	FRANCE	Medical Consumables
07/2025	PATRICIA INDUSTRIES	NOVA BIOMEDICAL	UNITED STATES	Diagnostic Equipment
05/2025	IK PARTNERS	BIOBANK	FRANCE	Implants & Prosthetics
05/2025	OTTOBOCK	MATTON ORTHOMEDI	BELGIUM	Implants & Prosthetics
04/2025	NORGINE	THERAVIA	FRANCE	Generics / Labs
04/2025	CINVEN	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Animal Health
04/2025	PATIENT SQUARE CAPITAL	PATTERSON COMPANIES	UNITED STATES	Medical Consumables
04/2025	IK PARTNERS	STERIMED	FRANCE	Medical Consumables

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 500M - 1b EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BIOGARAN by BC PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: biogaran

Acquirer: bc partners